← Back to Clinical Trials
Recruiting NCT05423444

NCT05423444 Neural Connectivity During Therapy for Adolescent PTSD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05423444
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition PTSD
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2022-11-29
Primary Completion 2027-02-28

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
TF-CBTTAU

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 180 participants in total. It began in 2022-11-29 with a primary completion date of 2027-02-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying cognitive, social and emotional skills. Neuroimaging research that seeks to identify the neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has been slow using current methods. The proposed study uses an innovative approach to identify neural mechanisms of specific phases of trauma-focused therapy for youth with PTSD, allowing a new understanding of brain changes associated with the process of therapy.

Eligibility Criteria

Inclusion Criteria: * ages 12-17 and Tanner stage 2 or above * history of interpersonal trauma * PTSD symptoms with a rating of '2' or higher on at least one symptom from each of the 4 clusters, using the Clinician-Administered PTSD Scale for Children and Adolescents, and having a duration of at least one month Exclusion Criteria: * current or past use of psychiatric medications * severe suicidal/homicidal ideation * current hospitalization * other current psychotherapy or previous treatment with TF-CBT * history of head injury with loss of consciousness for \>5 minutes * IQ\<85 * major medical illness * MRI contraindications (metal in body; braces on teeth) * psychosis, bipolar 1, autism, developmental disorder, panic disorder * first-degree family member with diagnosis of psychosis or bipolar I disorder * substance dependence within the past 3 months or current drug use that is frequent

Contact & Investigator

Central Contact

Amy Garrett, PhD

✉ garrettas@uthscsa.edu

📞 12105678189

Principal Investigator

Amy Garrett, PhD

PRINCIPAL INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Frequently Asked Questions

Who can join the NCT05423444 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 17 Years, studying PTSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05423444 currently recruiting?

Yes, NCT05423444 is actively recruiting participants. Contact the research team at garrettas@uthscsa.edu for enrollment information.

Where is the NCT05423444 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT05423444 clinical trial?

NCT05423444 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Amy Garrett, PhD at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 180 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology